(Q33794859)

29 July 2017

1 reference

title

Thrombolysis for acute stroke (English)

1 reference

29 July 2017

1 reference

Lyden PD

1 reference

29 July 2017

publication date

1 November 1999

1 reference

Progress in Cardiovascular Diseases

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

175-183

1 reference

Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

A pilot study of urokinase therapy in cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

The beneficial effect of intracarotid urokinase on acute stroke in a baboon model

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Tissue plasminogen activator reduces neurological damage after cerebral embolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Evaluation of recombinant tissue plasminogen activator in embolic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome After Embolic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Trials of streptokinase in severe acute ischaemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Termination of trial of streptokinase in severe acute ischaemic stroke. MAST Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Benefit-cost analysis of rubella vaccination policy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Pertussis Vaccine — An Analysis of Benefits, Risks and Costs

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Cost-benefit evaluations of vaccination programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Acute stroke--on the threshold of a therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis--not a panacea for ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Hea

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Practice advisory: thrombolytic therapy for acute ischemic stroke--summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Current emergency department management of stroke in Houston, Texas

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Ultra-rapid identification, triage, and enrollment of stroke patients into clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Assessment scales for the evaluation of stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

Acute hypertension promotes hemorrhagic transformation in a rabbit embolic stroke model: effect of labetalol

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2899%2970001-0

7 January 2021

10.1016/S0033-0620(99)70001-0

Identifiers

DOI

1 reference

29 July 2017

1 reference